Funding for this research was provided by:
Academy of Finland (325392, 325392, 328287)
Business Finland (6478/31/2019)
Received: 18 January 2022
Accepted: 15 May 2022
First Online: 15 June 2022
: Human iPSC-lines were used compliant with the Declaration of Helsinki of the WMA, 1964. Written informed consent was obtained from all the participants. MBE2968, MBE2960 and TOB0644 were generated upon approval from the human research ethics committees of the Royal Victorian Eye and Ear Hospital (11/1031H), University of Melbourne (1545394), University of Tasmania (H0014124), with the requirements of the National Health & Medical Research Council of Australia and conformed with the Declarations of Helsinki [CitationRef removed, CitationRef removed, CitationRef removed]. Ctrl 8, LL190, MAD1, MAD6, MAD8, ISOAD4 and ISOAD5 lines were generated upon approval from the committee on Research Ethics of Northern Savo Hospital district (license no. 123/2016) [CitationRef removed]. The other lines were obtained commercially. All animal experiments were performed in accordance with the EU Directive 2010/63/EU on the protection of animals used for scientific purposes and were approved and monitored by the Animal Experiment Board in Finland. All efforts were made to minimize the number of animals used and the wellbeing of animals was considered in all steps.
: Not applicable.
: Malm and Giniatullin are inventors of PCT patent application related to this topic.